FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377029017> ?p ?o ?g. }

• W4377029017 abstract "<div>Purpose:<p>Patients with metastatic uveal melanoma have limited therapeutic options and high mortality rate so new treatment options are needed.</p>Patients and Methods:<p>We previously reported that patients treated with the PD-1 inhibitor pembrolizumab and the histone deacetylase inhibitor entinostat in the PEMDAC trial, experienced clinical benefits if their tumor originated from iris or was wildtype for <i>BAP1</i> tumor suppressor gene. Here we present the 2-year follow-up of the patients in the PEMDAC trial and identify additional factors that correlate with response or survival.</p>Results:<p>Durable responses were observed in 4 patients, with additional 8 patients exhibiting a stable disease. The median overall survival was 13.7 months. Grade 3 adverse events were reported in 62% of the patients, but they were all manageable. No fatal toxicity was observed. Activity of thymidine kinase 1 in plasma was higher in patients with stable disease or who progressed on treatment, compared with those with partial response. Chemokines and cytokines were analyzed in plasma. Three chemokines were significantly different when comparing patients with and without response. One of the factors, CCL21, was higher in the plasma of responding patients before treatment initiation but decreased in the same patients upon treatment. In tumors, CCL21 was expressed in areas resembling tertiary lymphoid structures (TLS). High plasma levels of CCL21 and presence of TLS-like regions in the tumor correlated with longer survival.</p>Conclusions:<p>This study provides insight into durable responses in the PEMDAC trial, and describes dynamic changes of chemokines and cytokines in the blood of these patients.</p>Significance:<p>The most significant finding from the 2-year follow-up study of the PEMDAC trial was that high CCL21 levels in blood was associated with response and survival. CCL21 was also expressed in TLS-like regions and presence of these regions was associated with longer survival. These analyses of soluble and tumor markers can inform on predictive biomarkers needing validation and become hypothesis generating for experimental research.</p></div>" @default.
• W4377029017 created "2023-05-19" @default.
• W4377029017 creator A5014354451 @default.
• W4377029017 creator A5025004246 @default.
• W4377029017 creator A5026031146 @default.
• W4377029017 creator A5052059834 @default.
• W4377029017 creator A5055595135 @default.
• W4377029017 creator A5056540580 @default.
• W4377029017 creator A5062124149 @default.
• W4377029017 creator A5062578923 @default.
• W4377029017 creator A5067369652 @default.
• W4377029017 creator A5070275752 @default.
• W4377029017 creator A5072335960 @default.
• W4377029017 creator A5073664946 @default.
• W4377029017 creator A5085934310 @default.
• W4377029017 creator A5086298459 @default.
• W4377029017 date "2023-05-18" @default.
• W4377029017 modified "2023-09-29" @default.
• W4377029017 title "Data from Chemokine Analysis in Patients with Metastatic Uveal Melanoma Suggests a Role for CCL21 Signaling in Combined Epigenetic Therapy and Checkpoint Immunotherapy" @default.
• W4377029017 doi "https://doi.org/10.1158/2767-9764.c.6628509.v2" @default.
• W4377029017 hasPublicationYear "2023" @default.
• W4377029017 type Work @default.
• W4377029017 citedByCount "0" @default.
• W4377029017 crossrefType "posted-content" @default.
• W4377029017 hasAuthorship W4377029017A5014354451 @default.
• W4377029017 hasAuthorship W4377029017A5025004246 @default.
• W4377029017 hasAuthorship W4377029017A5026031146 @default.
• W4377029017 hasAuthorship W4377029017A5052059834 @default.
• W4377029017 hasAuthorship W4377029017A5055595135 @default.
• W4377029017 hasAuthorship W4377029017A5056540580 @default.
• W4377029017 hasAuthorship W4377029017A5062124149 @default.
• W4377029017 hasAuthorship W4377029017A5062578923 @default.
• W4377029017 hasAuthorship W4377029017A5067369652 @default.
• W4377029017 hasAuthorship W4377029017A5070275752 @default.
• W4377029017 hasAuthorship W4377029017A5072335960 @default.
• W4377029017 hasAuthorship W4377029017A5073664946 @default.
• W4377029017 hasAuthorship W4377029017A5085934310 @default.
• W4377029017 hasAuthorship W4377029017A5086298459 @default.
• W4377029017 hasBestOaLocation W43770290172 @default.
• W4377029017 hasConcept C121608353 @default.
• W4377029017 hasConcept C126322002 @default.
• W4377029017 hasConcept C13373296 @default.
• W4377029017 hasConcept C143998085 @default.
• W4377029017 hasConcept C203014093 @default.
• W4377029017 hasConcept C2776914184 @default.
• W4377029017 hasConcept C2777658100 @default.
• W4377029017 hasConcept C2777701055 @default.
• W4377029017 hasConcept C2780057760 @default.
• W4377029017 hasConcept C502942594 @default.
• W4377029017 hasConcept C71924100 @default.
• W4377029017 hasConceptScore W4377029017C121608353 @default.
• W4377029017 hasConceptScore W4377029017C126322002 @default.
• W4377029017 hasConceptScore W4377029017C13373296 @default.
• W4377029017 hasConceptScore W4377029017C143998085 @default.
• W4377029017 hasConceptScore W4377029017C203014093 @default.
• W4377029017 hasConceptScore W4377029017C2776914184 @default.
• W4377029017 hasConceptScore W4377029017C2777658100 @default.
• W4377029017 hasConceptScore W4377029017C2777701055 @default.
• W4377029017 hasConceptScore W4377029017C2780057760 @default.
• W4377029017 hasConceptScore W4377029017C502942594 @default.
• W4377029017 hasConceptScore W4377029017C71924100 @default.
• W4377029017 hasLocation W43770290171 @default.
• W4377029017 hasLocation W43770290172 @default.
• W4377029017 hasOpenAccess W4377029017 @default.
• W4377029017 hasPrimaryLocation W43770290171 @default.
• W4377029017 hasRelatedWork W2342781363 @default.
• W4377029017 hasRelatedWork W2607780130 @default.
• W4377029017 hasRelatedWork W2903811712 @default.
• W4377029017 hasRelatedWork W2915045061 @default.
• W4377029017 hasRelatedWork W2969782175 @default.
• W4377029017 hasRelatedWork W3153432702 @default.
• W4377029017 hasRelatedWork W3161613553 @default.
• W4377029017 hasRelatedWork W3215044659 @default.
• W4377029017 hasRelatedWork W4292373623 @default.
• W4377029017 hasRelatedWork W4312075079 @default.
• W4377029017 isParatext "false" @default.
• W4377029017 isRetracted "false" @default.
• W4377029017 workType "article" @default.